Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 317


Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L.

J Clin Psychiatry. 2015 Mar;76(3):253-62. doi: 10.4088/JCP.14m09416.


Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.

JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241.


Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.

Joshi K, Lin J, Lingohr-Smith M, Fu DJ.

J Med Econ. 2015;18(8):629-36. doi: 10.3111/13696998.2015.1033424. Epub 2015 Apr 22.


Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP.

J Clin Psychopharmacol. 2010 Oct;30(5):487-95. doi: 10.1097/JCP.0b013e3181eeb600.


Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.

Schizophr Res. 2010 Feb;116(2-3):107-17. doi: 10.1016/j.schres.2009.10.026. Epub 2009 Dec 2.


Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Fu DJ, Turkoz I, Simonson RB, Walling D, Schooler N, Lindenmayer JP, Canuso C, Alphs L.

J Clin Psychopharmacol. 2016 Aug;36(4):372-6. doi: 10.1097/JCP.0000000000000535.


Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL.

J Clin Psychiatry. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584.


Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.

Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L.

Schizophr Res. 2018 Feb;192:185-193. doi: 10.1016/j.schres.2017.04.004. Epub 2017 Apr 26.


Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).

Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trial 144 Study Investigators.

J Clin Psychiatry. 2011 Nov;72(11):1452-64. doi: 10.4088/JCP.11m06878. Erratum in: J Clin Psychiatry. 2014 Mar;75(3):290.


Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS.

JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310. Erratum in: JAMA. 2014 Oct 8;312(14):1473.


Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.

Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R; Aripiprazole Study Group.

J Clin Psychiatry. 2007 Oct;68(10):1480-91.


Paliperidone for the treatment of schizoaffective disorder.

Alphs L, Fu DJ, Turkoz I.

Expert Opin Pharmacother. 2016;17(6):871-83. doi: 10.1517/14656566.2016.1161029. Epub 2016 Mar 24. Review.


A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R; Aripiprazole Study Group.

J Clin Psychiatry. 2006 Apr;67(4):626-37.


A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.

Berwaerts J, Melkote R, Nuamah I, Lim P.

J Affect Disord. 2012 May;138(3):247-58. doi: 10.1016/j.jad.2012.01.047. Epub 2012 Feb 27.


Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW.

Int Clin Psychopharmacol. 2010 Sep;25(5):247-56. doi: 10.1097/YIC.0b013e32833948fa.


Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.

Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu DJ.

J Nerv Ment Dis. 2017 Apr;205(4):324-328. doi: 10.1097/NMD.0000000000000646.


Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW.

J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530.


Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.

Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L.

J Affect Disord. 2016 Mar 15;193:381-90. doi: 10.1016/j.jad.2015.12.060. Epub 2015 Dec 31.

Supplemental Content

Support Center